A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer

Pancreatic Cancer Clinical Trial

Official title:

A Study Evaluating Safety and Efficacy of Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Adenocarcinoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01025570
• Other study ID #: 09456
• Secondary ID: 10-00560
• Status: Terminated
• Phase: Phase 1
• First received: December 1, 2009
• Last updated: May 7, 2014
• Start date: May 2010
• Est. completion date: June 2013

Study information

• Verified date: May 2014
• Source: University of California, San Francisco
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to find out the effects, good and/or bad, of the combination of two drugs, gemcitabine and bosutinib, in patients with resected pancreatic cancer and whether this combination can prevent pancreatic cancer from coming back.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3
• Est. completion date: June 2013
• Est. primary completion date: May 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically proven adenocarcinoma of the pancreas.

• Complete resection by standard pancreaticoduodenectomy (for tumors of the pancreatic head) or distal pancreatectomy (for tumors of the pancreatic tail). Positive microscopic margins are allowable.

• No measurable disease.

• ECOG performance status 0 - 1.

• = 18 years of age.

• Ability to start adjuvant therapy within 8 weeks after pancreatic cancer surgery (but no sooner than 3 weeks).

• CA 19-9 = 2.5 times the upper limit of normal.

• ANC (absolute neutrophil count) = 1500/µL

• Hemoglobin = 9 gm/dL (may be transfused or may receive epoetin alfa to maintain this level)

• Platelet count = 100,000/µL

• INR = 1.5 (except those subjects who are receiving full-dose warfarin)

• Total bilirubin = 2.0 mg/dL

• AST and ALT = 2.5 times the upper limit of normal

• Serum creatinine = 2.0

• Negative pregnancy test for women of childbearing potential (serum or urine beta-HCG).

• All patients must be informed of the investigational nature of this study and sign and give written informed consent in accordance with institutional and federal guidelines.

• Women or men of reproductive potential must agree to use an effective contraceptive method during treatment and for 6 months afterwards.

• At least one paraffin block from patient's pancreatic cancer surgery must be available for analysis (does not necessarily need to be received by the start of study treatment).

Exclusion Criteria:

• Any prior systemic or investigational therapy for pancreatic cancer.

• Grossly positive surgical margins.

• Any of the following post-operative complications: wound dehiscence or infection, intraabdominal abscess, pancreatic or biliary leak or fistula.

• History of major psychiatric disorder or other chronic medical illness that, in the opinion of the treating physician, contraindicates the use of the investigational drugs in this protocol or that might render the subject at high risk of treatment related complications.

• Serious active ongoing infection, including any requiring parenteral antibiotics.

• Patients with a "currently active" second malignancy other than non-melanoma skin cancer. Patients are not considered to have a "currently active" malignancy if they have completed therapy and considered by their physician to be at less than 30% risk of relapse.

• Pregnancy (positive pregnancy test) or lactation.

• Known central nervous system disease.

• Inability to swallow pills/tolerate oral intake.

• Inability to comply with study and/or follow-up procedures.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• Gemcitabine, Bosutinib
Gemcitabine, 1000 mg/m2 on D1,8,15 over 30 mins standard infusion rate Bosutinib 400 mg, oral, once daily

Locations

Country	Name	City	State
United States	Huntsman Cancer Institute, University of Utah	Salt Lake City	Utah
United States	UCSF Helen Diller Family Comprehensive Cancer Center	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
University of California, San Francisco	University of Utah

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the safety of using the combination of gemcitabine and bosutinib in the postoperative adjuvant treatment of patients with completely resected pancreatic cancer.		8 weeks after the 6th patient is enrolled	Yes
Primary	To estimate the median disease-free survival rate of patients with completely resected pancreatic cancer treated with this combination		2 years after last patient is enrolled	No
Secondary	To determine the overall survival rates of patients with completely resected pancreatic cancer when treated postoperatively with the combination of gemcitabine and bosutinib		2 years after last patient is enrolled	No
Secondary	To estimate both disease-free and overall survival at one and two years of patients with completely resected pancreatic cancer treated with this combination		2 years after last patient is enrolled	No